SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
MENLO PARK, Calif., March 17, 2016 -- Geron Corporation (Nasdaq:GERN) today announced that two abstracts describing non-clinical data on imetelstat have been accepted for presentation as posters at the 2016 American Association of Cancer Research (AACR) Annual Meeting to be held in New Orleans, Louisiana from April 16-20, 2016. The abstracts are available on the AACR website at www.aacr.org.
Poster Presentations at AACR Annual Meeting
Session Title: Cell Cycle Control and Checkpoints
Session Date: Tuesday, April 19, 2016
Session Time: 8:00 a.m. ET -12:00 p.m. ET
Title: Impact of hypomethylating agents on hTERT expression and synergistic effect in combination with imetelstat, a telomerase inhibitor, in AML cell lines (Abstract #2731)
Title: Myelosuppression in patients treated with the telomerase inhibitor imetelstat is not mediated through activation of toll-like receptors (Abstract #2732)
In accordance with AACR policies, abstracts submitted to the AACR Annual Meeting are embargoed from the time of submission. To be eligible for presentation at the AACR Annual Meeting, information contained in the abstract, as well as additional data and information to be presented at the Annual Meeting, may not be made public before the abstract has been presented in connection with the AACR Annual Meeting.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
